FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007448466> ?p ?o ?g. }

• W2007448466 endingPage "120" @default.
• W2007448466 startingPage "112" @default.
• W2007448466 abstract "The cell adhesion molecule integrin αvβ3 is an important player in the process of tumor angiogenesis and metastasis. Abegrin™, a fully humanized anti-integrin αvβ3 monoclonal antibody, was currently in clinical trials for cancer therapy. Herein, we labeled Abegrin™ with 111In, evaluated the in vitro and in vivo characteristics, and investigated whether the expression of integrin αvβ3 in tumors could be imaged with 111In-labeled Abegrin™. The binding affinity and specificity of Abegrin™ was analyzed using U87MG glioblastoma cells. Abegrin™ was coupled with 1,4,7,10-tetraazadodecane-N,N′,N″,N′″-tetraacetic acid (DOTA) for 111In radiolabeling. γ Imaging of 111In-DOTA–Abegrin™ was carried out in nude mice bearing both integrin αvβ3-positive U87MG and integrin αvβ3-negative HT-29 tumors. Biodistribution and blocking studies of 111In-DOTA–Abegrin™ were investigated in U87MG tumor-bearing nude mice. Abegrin™ exhibited high-binding affinity to human integrin αvβ3 expressed on U87MG cells (K d of 0.35 ± 0.06 nM). The antibody retained antigen-binding affinity/specificity after DOTA conjugation. γ Imaging showed that the tumor uptake of 111In-DOTA–Abegrin™ in integrin αvβ3-positive U87MG tumors was much higher than that in integrin αvβ3-negative HT-29 tumors. In the HT-29 tumors, Abegrin™ was mainly nonspecifically accumulated around the blood vessels, while in the U87MG tumors, besides the nonspecific tumor retention, Abegrin™ also specifically bound the human integrin αvβ3 expressed on the tumor cells. Biodistribution and blocking studies exhibited that the U87MG tumor uptake of 111In-DOTA–Abegrin™ decreased from 14.12 ± 0.44 to 6.93 ± 0.94 percentage of injected dose per gram of tissue after coinjection of excess dose of cold Abegrin™, which confirmed the in vivo integrin αvβ3 binding specificity of 111In-DOTA–Abegrin™. Abegrin™ showed specific binding to human integrin αvβ3 expressed on the tumor cells. 111In-DOTA–Abegrin™ can specifically target the human integrin αvβ3 expression in the nude mouse model. 111In-DOTA–Abegrin™ has a potential for clinical translation as an agent for integrin αvβ3-positive tumor imaging, evaluating tumor angiogenic status and monitoring the therapeutic efficacy of Abegrin™-based cancer therapy." @default.
• W2007448466 created "2016-06-24" @default.
• W2007448466 creator A5018249388 @default.
• W2007448466 creator A5022268901 @default.
• W2007448466 creator A5022600083 @default.
• W2007448466 creator A5037753129 @default.
• W2007448466 creator A5063512998 @default.
• W2007448466 date "2010-04-10" @default.
• W2007448466 modified "2023-09-24" @default.
• W2007448466 title "Specific Targeting of Human Integrin αvβ3 with 111In-Labeled Abegrin™ in Nude Mouse Models" @default.
• W2007448466 cites W147592962 @default.
• W2007448466 cites W1963810538 @default.
• W2007448466 cites W1970267589 @default.
• W2007448466 cites W1975429911 @default.
• W2007448466 cites W1977125553 @default.
• W2007448466 cites W1977703188 @default.
• W2007448466 cites W1981942027 @default.
• W2007448466 cites W1987355699 @default.
• W2007448466 cites W1990506324 @default.
• W2007448466 cites W1997449859 @default.
• W2007448466 cites W2003366243 @default.
• W2007448466 cites W2029231027 @default.
• W2007448466 cites W2029773366 @default.
• W2007448466 cites W2031878658 @default.
• W2007448466 cites W2037048276 @default.
• W2007448466 cites W2040483132 @default.
• W2007448466 cites W2042382954 @default.
• W2007448466 cites W2043720960 @default.
• W2007448466 cites W2046690431 @default.
• W2007448466 cites W2062301515 @default.
• W2007448466 cites W2077237687 @default.
• W2007448466 cites W2085355242 @default.
• W2007448466 cites W2087360616 @default.
• W2007448466 cites W2091492240 @default.
• W2007448466 cites W2094463376 @default.
• W2007448466 cites W2100363932 @default.
• W2007448466 cites W2105923744 @default.
• W2007448466 cites W2107413864 @default.
• W2007448466 cites W2116290973 @default.
• W2007448466 cites W2127802941 @default.
• W2007448466 cites W2136632737 @default.
• W2007448466 cites W2136713923 @default.
• W2007448466 cites W2140859605 @default.
• W2007448466 cites W2164481004 @default.
• W2007448466 cites W2168198903 @default.
• W2007448466 cites W4213141530 @default.
• W2007448466 cites W9050420 @default.
• W2007448466 doi "https://doi.org/10.1007/s11307-010-0302-4" @default.
• W2007448466 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5242344" @default.
• W2007448466 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20383594" @default.
• W2007448466 hasPublicationYear "2010" @default.
• W2007448466 type Work @default.
• W2007448466 sameAs 2007448466 @default.
• W2007448466 citedByCount "24" @default.
• W2007448466 countsByYear W20074484662012 @default.
• W2007448466 countsByYear W20074484662013 @default.
• W2007448466 countsByYear W20074484662014 @default.
• W2007448466 countsByYear W20074484662017 @default.
• W2007448466 countsByYear W20074484662018 @default.
• W2007448466 countsByYear W20074484662021 @default.
• W2007448466 countsByYear W20074484662022 @default.
• W2007448466 crossrefType "journal-article" @default.
• W2007448466 hasAuthorship W2007448466A5018249388 @default.
• W2007448466 hasAuthorship W2007448466A5022268901 @default.
• W2007448466 hasAuthorship W2007448466A5022600083 @default.
• W2007448466 hasAuthorship W2007448466A5037753129 @default.
• W2007448466 hasAuthorship W2007448466A5063512998 @default.
• W2007448466 hasBestOaLocation W20074484662 @default.
• W2007448466 hasConcept C147483822 @default.
• W2007448466 hasConcept C1491633281 @default.
• W2007448466 hasConcept C150903083 @default.
• W2007448466 hasConcept C153911025 @default.
• W2007448466 hasConcept C159654299 @default.
• W2007448466 hasConcept C185592680 @default.
• W2007448466 hasConcept C195687474 @default.
• W2007448466 hasConcept C202751555 @default.
• W2007448466 hasConcept C203014093 @default.
• W2007448466 hasConcept C207001950 @default.
• W2007448466 hasConcept C2777807558 @default.
• W2007448466 hasConcept C2779931791 @default.
• W2007448466 hasConcept C502942594 @default.
• W2007448466 hasConcept C542903549 @default.
• W2007448466 hasConcept C55493867 @default.
• W2007448466 hasConcept C71924100 @default.
• W2007448466 hasConcept C86803240 @default.
• W2007448466 hasConceptScore W2007448466C147483822 @default.
• W2007448466 hasConceptScore W2007448466C1491633281 @default.
• W2007448466 hasConceptScore W2007448466C150903083 @default.
• W2007448466 hasConceptScore W2007448466C153911025 @default.
• W2007448466 hasConceptScore W2007448466C159654299 @default.
• W2007448466 hasConceptScore W2007448466C185592680 @default.
• W2007448466 hasConceptScore W2007448466C195687474 @default.
• W2007448466 hasConceptScore W2007448466C202751555 @default.
• W2007448466 hasConceptScore W2007448466C203014093 @default.
• W2007448466 hasConceptScore W2007448466C207001950 @default.
• W2007448466 hasConceptScore W2007448466C2777807558 @default.
• W2007448466 hasConceptScore W2007448466C2779931791 @default.
• W2007448466 hasConceptScore W2007448466C502942594 @default.

• next